Cabaletta Bio (CABA) Income from Non-Controlling Interests (2020 - 2025)
Cabaletta Bio's (CABA) quarterly Income from Non-Controlling Interests came in at $2000.0 in Q4 2025, up 300.0% year-on-year from $500.0 in Q4 2024, and down 90.91% quarter-over-quarter from $22000.0 in Q3 2025.
Cabaletta Bio (CABA) Income from Non-Controlling Interests (2020 - 2025) Analysis & Trends
Cabaletta Bio's Income from Non-Controlling Interests history runs 6 years deep, the most recent figure standing at $2000.0 for Q4 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 300.0% year-over-year to $2000.0 in Q4 2025; TTM through Dec 2025 was $25000.0, a 164.1% increase from a year earlier, with the FY2025 full-year figure at $25000.0, up 164.1% from the prior year.
- Income from Non-Controlling Interests eased to $2000.0 in Q4 2025 per CABA's latest filing, from $22000.0 in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $162000.0 in Q4 2022 and bottomed at -$152000.0 in Q1 2022.
- The 5-year median for Income from Non-Controlling Interests is $1000.0 (2021), against an average of $3947.4.
- Biggest YoY gain for Income from Non-Controlling Interests was 4100.0% in 2022; the steepest drop was 9800.0% in 2022.
- Year by year, Income from Non-Controlling Interests stood at $6000.0 in 2021, then soared by 2600.0% to $162000.0 in 2022, then plunged by 33.95% to $107000.0 in 2023, then plunged by 100.93% to -$1000.0 in 2024, then surged by 300.0% to $2000.0 in 2025.
- Per Business Quant, the three latest CABA Income from Non-Controlling Interests figures stand at $2000.0 (Q4 2025), $22000.0 (Q3 2025), and $1000.0 (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cabaletta Bio | 182.04 Mn | 182.04 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,000.00 |
| Sep 30, 2025 | 22,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 9,000.00 |
| Mar 31, 2024 | -77,000.00 |
| Dec 31, 2023 | 107,000.00 |
| Sep 30, 2023 | -18,000.00 |
| Jun 30, 2023 | -3,000.00 |
| Mar 31, 2023 | 47,000.00 |
| Dec 31, 2022 | 162,000.00 |
| Sep 30, 2022 | 40,000.00 |
| Jun 30, 2022 | -97,000.00 |
| Mar 31, 2022 | -152,000.00 |
| Dec 31, 2021 | 6,000.00 |
| Sep 30, 2021 | -1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | -3,000.00 |
| Dec 31, 2020 | -6,000.00 |